Live feed
Filing
SCHEDULE 13D
SCHEDULE 13D0001193125-25-285070·Fairmount Funds Management LLC
Schedule 13D ownership disclosure
DAMORA THERAPEUTICS INC
Common Stock, par value par value $0.00001 per share · CUSIP: 36322Q206
Event date: 2025-11-10
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Fairmount Funds Management LLCReported CIK 0001802528
Shares: 397,000.00 · Class: 19.99%
- Fairmount Healthcare Fund II L.P.Reported CIK 0001769651
Shares: 397,000.00 · Class: 19.99%
- Fairmount Healthcare Co-Invest V L.P.Reported CIK 0002091559
Shares: 397,000.00 · Class: 19.99%
- Peter Evan HarwinReported CIK 0001663607
Shares: 397,000.00 · Class: 19.99%
- Tomas KiselakReported CIK 0001830177
Shares: 397,000.00 · Class: 19.99%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-25-285070
- Form type
- SCHEDULE 13D
- Filer
- Fairmount Funds Management LLC
- CIK
- CIK 1802528
- Filed
- Nov 17, 2025
- Reporting period
- Nov 10, 2025
- Description
- Schedule 13D beneficial ownership